Patent Term Application for VYLOY (zolbetuximab-clzb), Patent No. 10,022,444 | Federal Regulations · Congress.wiki

Nonrulemaking

FDA

Open for Comments

FDA-2025-E-0867

Patent Term Application for VYLOY (zolbetuximab-clzb), Patent No. 10,022,444

Documents

Comments

Description

OPEN

Comment Period OpensMar 26, 2025

Comment Period ClosesJun 3, 2026

Type	Title	Posted	Comments	Status
Notice	Determination of Regulatory Review Period for Purposes of Patent Extension; VYLOY FR Doc: 2026-06478	Apr 3, 2026	--

CDER

Patent Term Application

VYLOY (zolbetuximab-clzb)

Neal, Gerber & Eisenberg LLP

Astellas Pharma Inc

TRON – Translationale Onkologie an der

Universitatesmedizin der Johannes

Gutenberg-Universitat Mainz Gemeinnutzige GmbH